Peter Ström
AstraZeneca (Sweden)(SE)
Publications by Year
Research Areas
Neuroscience and Neuropharmacology Research, Receptor Mechanisms and Signaling, Asymmetric Synthesis and Catalysis, Neurotransmitter Receptor Influence on Behavior, Cancer Treatment and Pharmacology
Most-Cited Works
- → Proenkephalin A gene products activate a new family of sensory neuron–specific GPCRs(2002)381 cited
- → AZD2184: a radioligand for sensitive detection of β‐amyloid deposits(2008)120 cited
- → Synthesis of [methoxy‐3H]‐ and [methoxy‐11C]‐ labelled raclopride. Specific dopamine‐D2 receptor ligands(1987)86 cited
- → A Comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding(1991)62 cited
- → NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors(1991)61 cited
- → Discovery and characterization of AZD9272 and AZD6538—Two novel mGluR5 negative allosteric modulators selected for clinical development(2012)38 cited
- → 2,2'-Dimethyl-6,6'-bis(diphenylphosphino)biphenyl (BIPHEMP) as a Chiral Ligand for Transition Metal Catalyzed Asymmetric Synthesis of Binaphthyls and for Asymmetric Hydrogenation. A Comparison with BINAP.(1989)35 cited
- → Sulphation of o‐desmethylnaproxen and related compounds by human cytosolic sulfotransferases(2005)29 cited
- → Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners(1991)22 cited
- → Potential antipsychotic agents. Part 8. Antidopaminergic properties of a potent series of 5‐substituted (−)‐(S)‐N‐[(1‐ethylpyrrolidin‐2‐yl)methyl]‐2,3‐dimethoxybcnzaimides. Synthesis via common lithio intermediates(1990)20 cited